NCT00590824View on ClinicalTrials.gov

Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 17, 2007

Primary Completion Date

September 20, 2018

Study Completion Date

September 20, 2018

Conditions
Melanoma
Interventions
DRUG

hu14.18-IL2

6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2

DRUG

hu14.18-IL2

Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course

Trial Locations (1)

53792

University of Wisconsin Hospitals and Clinics, Madison

Sponsors

Collaborators (1)

EMD Serono
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

EMD Serono

INDUSTRY

lead

University of Wisconsin, Madison

OTHER

NCT00590824 - Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter